Latest Clinical Trials
MDMA for AUD/PTSD Comorbidity Carolina L Haass-Koffler NA
COMPLETED
(Sep 1, 2026)
PHASE2 Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients Medical University of South Carolina NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Study of Cannabidiol and Neuroimaging on Stress Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer West China Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery West China Hospital NA
RECRUITING
(Sep 1, 2026)
PHASE1 Pharmacokinetics of Zoledronic Acid in Patients on Dialysis University of Campinas, Brazil NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC West China Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Endocannabinoids in Reward Medical University of South Carolina NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration Qilu Pharmaceutical (Hainan) Co., Ltd. NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma West China Hospital NA
NOT YET RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer Cedars-Sinai Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders Medical University of South Carolina NA
COMPLETED
(Aug 1, 2026)
PHASE2 Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants Mount Sinai Hospital, Canada NA
RECRUITING
(Aug 1, 2026)
PHASE2 Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt Regina Elena Cancer Institute NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy West China Hospital NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 Different Medications to Induce Labor Icahn School of Medicine at Mount Sinai NA
COMPLETED
(Aug 1, 2026)
PHASE3 AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma West China Hospital NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) University of North Carolina, Chapel Hill NA
RECRUITING
(Aug 1, 2026)
PHASE2 Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers Regina Elena Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE3 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Aug 1, 2026)
PHASE3 Oral Ketorolac for IUD Pain Reduction University of North Carolina, Chapel Hill NA
ENROLLING BY INVITATION
(Aug 1, 2026)
PHASE2 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Cedars-Sinai Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation Icahn School of Medicine at Mount Sinai NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 The DART DELIVER-02 Study University of North Carolina, Chapel Hill NA
SUSPENDED
(Aug 1, 2026)
PHASE1 PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Kristina A. Fanucci NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis University of North Carolina, Chapel Hill NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Aug 1, 2026)
PHASE2 E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study University of North Carolina, Chapel Hill NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Medical University of South Carolina NA
RECRUITING
(Aug 1, 2026)
PHASE2 BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 DOSE-UP: Dose Optimization for Smoking and E-Cigarette Use Pharmacotherapy Medical University of South Carolina NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial West China Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women Associação Pan-Americana Multidisciplinar de Endocanabinologia NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Icahn School of Medicine at Mount Sinai NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Oxytocin to Enhance Integrated Treatment for AUD and PTSD Medical University of South Carolina NA
COMPLETED
(Jul 1, 2026)
PHASE2 Kisspeptin Administration Subcutaneously to Patients With IHH Stephanie B. Seminara, MD NA
RECRUITING
(Jul 1, 2026)
PHASE2 Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors Medical University of South Carolina NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients Medical University of South Carolina NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Jul 1, 2026)
PHASE2 Deucravacitinib in the Treatment of Cicatricial Alopecias Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Jul 1, 2026)
PHASE2 CBD Supplementation in Brazilian Jiu-Jitsu Athletes Associação Pan-Americana Multidisciplinar de Endocanabinologia NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma Jinling Hospital, China NA
RECRUITING
(Jul 1, 2026)
PHASE2 Research on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis China-Japan Friendship Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Cannabidiol Oil for Treatment-Resistant Major Depression Universidade do Sul de Santa Catarina NA
RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression West China Hospital NA
RECRUITING
(Jul 1, 2026)
PHASE2 Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) West China Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3 Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Medical University of South Carolina NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients Cullinan Therapeutics Inc. NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Shanghai General Hospital, China NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma West China Hospital NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder NinaMED Pty Ltd NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 RegoNivo vs Standard of Care Chemotherapy in AGOC Australasian Gastro-Intestinal Trials Group NA
COMPLETED
(Jun 1, 2026)
PHASE3 Cannabidiol for Reducing Drinking in Alcohol Use Disorder Hôpital le Vinatier NA
TERMINATED
(Jun 1, 2026)
PHASE2 CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Cullinan Therapeutics Inc. NA
TERMINATED
(Jun 1, 2026)
PHASE1 Dose Optimization of Caffeine for HIE University of North Carolina, Chapel Hill NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab Regina Elena Cancer Institute NA
RECRUITING
(Jun 1, 2026)
PHASE2 Chemo-Radiotherapy Boost Treatment Guided by Perfusion MRI on Hypoxic Zones in Head and Neck Cancer Regina Elena Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Jun 1, 2026)
PHASE2 Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents Children's Cancer Group, China NA
RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3 18F-mFBG Cardiac Uptake With Lewy Body Dementia Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) NA
RECRUITING
(Jun 1, 2026)
PHASE2 Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD NA
RECRUITING
(Jun 1, 2026)
PHASE3 Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1 Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors West China Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE1 Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial Southeast University, China NA
RECRUITING
(Jun 1, 2026)
PHASE3 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 How Precision Diets, Through Gut Bacteria, Affect Anemia in Nepalese Adolescent Southern Medical University, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer West China Hospital NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Medical University of South Carolina NA
NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Vaccination With Flt3L, Radiation, and Poly-ICLC Icahn School of Medicine at Mount Sinai NA
COMPLETED
(May 1, 2026)
PHASE1, PHASE2 COAST Therapy in Advanced Solid Tumors and Prostate Cancer Medical University of South Carolina NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Citicoline in Youth Alcohol Use Disorder Medical University of South Carolina NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC West China Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 SAMe in Prevention of Oxaliplatin-associated Liver Injury Cedars-Sinai Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study Australasian Gastro-Intestinal Trials Group NA
RECRUITING
(May 1, 2026)
PHASE2 Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) Australasian Gastro-Intestinal Trials Group NA
RECRUITING
(May 1, 2026)
PHASE2 A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE2 HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients Medical University of South Carolina NA
RECRUITING
(May 1, 2026)
PHASE2 Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma Medical University of South Carolina NA
RECRUITING
(May 1, 2026)
PHASE2 Sex Differences in Neurobehavioral Response to THC Medical University of South Carolina NA
TERMINATED
(May 1, 2026)
PHASE2 Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE2 Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(May 1, 2026)
PHASE2 Clinical Observation of Bupivacaine Liposome for Lower Extremity Nerve Block Hainan Medical College NA
COMPLETED
(May 1, 2026)
PHASE2 A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma Catalina Lee Chang NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1 Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus First Hospital of China Medical University NA
RECRUITING
(May 1, 2026)
PHASE2 Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery Icahn School of Medicine at Mount Sinai NA
RECRUITING
(May 1, 2026)
PHASE3 Using Mirabegron to Control Arrhythmia-1 Cedars-Sinai Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors West China Hospital NA
RECRUITING
(May 1, 2026)
PHASE1 Beta-3 Enhanced Autonomic Therapy for POTS Cedars-Sinai Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia Institute of Hematology & Blood Diseases Hospital, China NA
WITHDRAWN
(May 1, 2026)
PHASE1, PHASE2 A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) Universidade do Sul de Santa Catarina NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Effect of Remimazolam Sedation on Outcomes of Mechanically Ventilated Patients in the ICU Southeast University, China NA
RECRUITING
(May 1, 2026)
PHASE3 Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. Shanghai Pulmonary Hospital, Shanghai, China NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC West China Hospital NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells Medical University of South Carolina NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer Arvinas Estrogen Receptor, Inc. NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China NA
COMPLETED
(Apr 1, 2026)
PHASE2, PHASE3 The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication Louis Messina NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer SUNHO（China）BioPharmaceutical CO., Ltd. NA
RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis Talengen Institute of Life Sciences, Shenzhen, P.R. China. NA
RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 BXCL501 After Stress to Increase Recovery Success University of North Carolina, Chapel Hill NA
RECRUITING
(Apr 1, 2026)
PHASE2 Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor Kristina Simonyan NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 Mast Cell Treatment in Post-tick Bite Illness (PTBI) University of North Carolina, Chapel Hill NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1 Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases: The Second Affiliated Hospital of Hainan Medical University NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Apr 1, 2026)
PHASE3 Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) China Medical University Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer Air Force Military Medical University, China NA
RECRUITING
(Apr 1, 2026)
PHASE2 Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity Icahn School of Medicine at Mount Sinai NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC West China Hospital NA
NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 TAIC FOLFOX for Locally Advanced G/GEJA Guang'anmen Hospital of China Academy of Chinese Medical Sciences NA
RECRUITING
(Apr 1, 2026)
PHASE2 BNHL-2015 for Children or Adolescents in China Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3 LBL-2016 for Children or Adolescents in China Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD) Medical University of South Carolina NA
COMPLETED
(Mar 1, 2026)
PHASE2 CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL Children's Cancer Group, China NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3 Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia China Medical University Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE2 Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) Cedars-Sinai Medical Center NA
RECRUITING
(Mar 1, 2026)
PHASE2 Safety and Efficacy of Faricimab in Patients With NPDR Greater Houston Retina Research NA
COMPLETED
(Mar 1, 2026)
PHASE2 Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis Air Force Military Medical University, China NA
COMPLETED
(Mar 1, 2026)
PHASE3 Using Mirabegron to Increase BP in Patients With POTS Cedars-Sinai Medical Center NA
COMPLETED
(Mar 1, 2026)
PHASE2 Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study University of North Carolina, Chapel Hill NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 China Medical University Hospital NA
COMPLETED
(Mar 1, 2026)
PHASE1 Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas West China Hospital NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1 Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 Icahn School of Medicine at Mount Sinai NA
RECRUITING
(Mar 1, 2026)
PHASE3 VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Institute of Hematology & Blood Diseases Hospital, China NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Tolerability & Pharmacokinetics of Ginkgolide B Injection: Single- and Multiple-Ascending Doses in Healthy Subjects West China Second University Hospital NA
COMPLETED
(Mar 1, 2026)
PHASE1 GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study West China Hospital NA
RECRUITING
(Mar 1, 2026)
PHASE1 Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia Institute of Hematology & Blood Diseases Hospital, China NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients Shanghai Pulmonary Hospital, Shanghai, China NA
NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 CREON for the Treatment of Post-RYGB Hypoglycemia East Carolina University NA
TERMINATED
(Oct, 2023)
PHASE1 Alexa, What is Eliquis and Xarelto? Cedars-Sinai Medical Center NA
TERMINATED
(Mar, 2022)
NA 
